Back

Effects of Sacubitril/Valsartan on all-cause hospitalizations in heart failure: participant-level pooled analysis of PARADIGM-HF and PARAGON-HF

30 August 2024 (12:00 - 12:50)
Organised by: Logo
Congress Presentation Part of: Drug therapy for heart failure: what is new? Treatment ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Henri Lu

Lausanne University Hospital, Lausanne (Switzerland)

8 More presentations in this session

Presentation thumbnail
Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population
Professor M. Crespo-Leiro (A Coruna, ES)
Abstract Slides Video
Presentation thumbnail
Efficacy of sotagliflozin by diabetes duration: a secondary analysis of SCORED
Doctor R. Aggarwal (Boston, US)
Abstract Slides Video
Presentation thumbnail
Effects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER
Doctor J. Butt (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Long-term follow-up of the TRED-HF trial
Miss L. Cheng (London, GB)
Abstract Slides Video
Presentation thumbnail
Utilization and safety of digoxin in patients with chronic heart failure and atrial fibrillation with rapid ventricular rate
Doctor K. Berge (Nordbyhagen, NO)
Abstract Slides Video

Access the full session

Session thumbnail
Drug therapy for heart failure: what is new?

The Event

Event poster

ESC Congress 2024

30 August 2024 12:00 CET
You may be interested in
thumbnail
Congress Presentation
PARAGLIDEHF: Sacubitril/Valsartan versus valsartan on changes in NTproBNP, safety, and tolerability in patients with EF>40% stabilized after a WHF Event
thumbnail
Congress Presentation
Outcomes and effects of sacubitril/valsartan according to NT-proBNP level in patients with heart failure: a patient-level pooled analysis of the PARADIGM-HF and PARAGON-HF trials
thumbnail
Congress Presentation
Sacubitril/valsartan vs. valsartan initiation in patients with heart failure and EF>40% who are naive to renin-angiotensin-system inhibitors: Insights from PARAGLIDE-HF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources